The study will investigate the efficacy of oral levosimendan in patients with chronic New
York Heart Association (NYHA) IIIb-IV heart failure (HF) using a composite end-point
evaluating patient symptoms, morbidity and mortality. The patients are on treatment for at
least 6 months.